SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Trump Says Anthropic No Longer Seen as National Security Threat 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
NEW YORK, Dec. 03, 2015 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of XBiotech Inc. (“XBiotech”) (Nasdaq:XBIT) between April 15, 2015 and November 23, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Western District of Texas. If you purchased or otherwise acquired XBiotech securities between April 15, 2015 and November 23, 2015, your rights may be affected by this action. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
According to the complaint, the Company made materially false and misleading statements to investors and/or failed to disclose that: (1) a fewer number of per protocol patients were available for primary endpoint evaluation in the Phase III Study; (2) the data from 72 patients of the Phase III Study was compromised; (3) XBiotech did not adequately sample patients to accommodate data loss; and (4) as a result of not properly sampling patients, the Phase III Study would have reduced statistical power to demonstrate the proposed outcome.
If you suffered a loss in XBiotech you have until February 1, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
